Portfolio Companies
Our carefully selected portfolio represents innovative companies with core technological barriers, broad market potential, and outstanding management teams across healthcare, biotechnology, and advanced technology sectors.
Neuro-AI
Fasikl
Neuro-AI / Brain-Computer Interface
Fasikl is a Minneapolis-based Neuro-AI technology company spun out of the University of Minnesota in 2019, and the world's first company to receive FDA clearance for an AI-powered brain-machine interface medical device. Its flagship product, the Felix NeuroAI Wristband, is a non-invasive wearable peripheral nerve stimulator that uses a cloud-based AI platform and closed-loop "brain-AI co-adaptation" to dynamically adjust electrical stimulation in real time. In the pivotal TRANQUIL study conducted across 12 sites in the US and China, the device demonstrated statistically significant efficacy (P<0.0001) with 69.4% of patients showing meaningful improvement versus 44.4% in the sham group. Beyond essential tremor, Fasikl is developing the Fasikl-X Nerve-Computer Interface platform targeting paralysis, chronic pain, and prosthetic limb control.
Investment Thesis: First-mover in FDA-cleared AI-BMI wearable therapeutics, with compelling clinical evidence from a randomized controlled trial and a pipeline extending into paralysis and chronic pain.
Healthcare Services
New Frontier Health Corporation
Premium Healthcare Services
New Frontier Health Corporation is a Hong Kong-headquartered premium healthcare platform operating one of China's largest integrated private healthcare networks. Founded in 2016 and listed on the NYSE, the company acquired United Family Healthcare (UFH) — founded in 1997 as one of China's first international-standard private hospitals — in a landmark $1.44 billion transaction. Today, UFH operates 11 general hospitals, 5 oncology centres, and over 20 clinics, serving more than 1 million patients annually. The broader New Frontier Group encompasses 22 rehabilitation hospitals and 300+ home care stations across 92 cities, with nearly 15 million patient visits per year. Recent strategic milestones include the acquisition of Hong Kong Integrated Oncology Centre (2024), cross-border GBA healthcare partnerships with Blue Cross and FWD (2025), and two flagship hospitals in Shenzhen (73,000 m²) and Guangzhou (60,000+ m²). In 2024, Warburg Pincus acquired Fosun Pharma's stake for $124 million, underscoring institutional confidence in the platform.
Investment Thesis: Dominant position in China's premium healthcare market with unmatched scale, cross-border GBA integration, and a proven M&A-driven growth model validated by top-tier institutional investors.
Biotechnology
Suzhou Abogen Biosciences Co., Ltd.
mRNA Technology / Drug Discovery
Suzhou Abogen Biosciences is one of China's most well-capitalized mRNA biotechnology companies, having raised over $1 billion including a record $700 million Series C round. Founded in 2019, Abogen achieved a historic milestone with ARCoV/AWcorna — China's first mRNA vaccine to receive overseas marketing authorization (Indonesia EUA, 2022). The company owns a fully integrated mRNA technology platform encompassing proprietary base modification chemistry (breaking the m1Ψ patent barrier in 2025), a domestically developed LNP delivery system validated in large-scale Phase III trials, and a lyophilized formulation technology enabling 2–8°C storage stability for over two years. Its rapidly maturing pipeline spans prophylactic vaccines (RSV Phase I/II, shingles Phase I), therapeutic cancer vaccines (pan-KRAS ABO2102 with dual FDA-NMPA IND clearance), and mRNA-encoded T cell engagers for autoimmune diseases (ABO2203 targeting SLE and rheumatoid arthritis). With approximately 10 prophylactic vaccines and multiple therapeutic candidates in development, Abogen represents one of the broadest mRNA pipelines in Asia.
Investment Thesis: Leading independent mRNA platform in Asia with proprietary chemistry, validated LNP delivery, industry-leading lyophilization technology, and a diversified pipeline spanning infectious disease, oncology, and autoimmune indications.